Tatva Chintan Pharma Chem sees negative performance in Q1 FY25 financial results

Tatva Chintan Pharma Chem, a smallcap company in the chemicals industry, recently announced its financial results for the quarter ending June 2024. According to the latest report, the company has seen a negative performance in this quarter, with a score of -17 compared to -11 in the previous three months.

One of the major factors contributing to this decline is the Profit Before Tax (PBT) less Other Income, which has fallen by 37.4% to Rs 5.64 crore from the average PBT of the previous four quarters, which was Rs 9.01 crore. This trend is expected to continue in the near term.

Similarly, the Profit After Tax (PAT) has also seen a decline of 31.3% to Rs 5.21 crore from the average PAT of the previous four quarters, which was Rs 7.59 crore. This indicates a negative trend in the company’s profitability.

Another concerning aspect is the Operating Profit Margin, which is at its lowest in the last five quarters at 11.97%. This suggests a deterioration in the company’s efficiency.

In terms of liquidity, Tatva Chintan’s Cash and Cash Equivalents have also seen a decline, reaching its lowest at Rs 38.29 crore in the last six half-yearly periods. This indicates a deteriorating short-term liquidity for the company.

Based on these financial results, MarketsMOJO has given a ‘Strong Sell’ call for Tatva Chintan’s stock. It is important for investors to carefully consider these factors before making any investment decisions.